IONTAS is a privately owned, profitable, biotechnology company, offering services and technologies to the global biotechnology community. Our expertise focuses on phage display and technologies for therapeutic antibody discovery. IONTAS scientific staff have been at the forefront of phage display technology, mammalian display and generating antibodies against ion channels
Stabilitech has developed a proprietary technology for stabilisation of vaccines and biopharmaceuticals, removing the need for refrigeration.. . Stabilitech started research in late 2004, and received its first significant funding in 2007, from business angels. . Stabilitech has developed a novel proprietary technology which stabilizes vaccines (including live viruses, inactivated viruses and subunit vaccines), biopharmaceuticals (including antibodies, enzymes, growth factors etc) and other biological products. . Stabilitech is based in the Imperial College incubator, and currently has 5 employees.
No data available
Isogenica partners with leading pharmaceutical and biotechnology companies in the early-stage discovery of novel biopharmaceuticals. . . Isogenica’s partners can access a range of innovative, highly-diverse, antibody libraries as an excellent starting point for new biotherapeutic development programmes.. . All the company’s libraries are fully synthetic, designed using state-of-the-art principles and built using the company’s highly precise Colibra oligonucletotide contruction technology. The combination of advanced design and accurate synthetic build technology minimises immunological biases, inevitable when using in vivo systems, and optimises the chances of generating high-affinity and developable drug candidates at the outset.. . The company’s proprietary antibody libraries are complemented with the option to use a proprietary in vitro antibody display system (CIS Display) which maintains the high diversity of the library through the discovery process. CIS Display is also available for licensing as a standalone technology.. . Isogenica currently has a range of camelid single domain antibody (VHH) libraries, and a range of human antibody fragment libraries. The company continues to innovate in the design and construction of new, advanced antibody libraries.
Isomerase is a synthetic biology and bioprocess innovation partner helping companies develop new products or processes through harnessing bacteria and fungi to discover and produce native or novel molecules sustainably, cost effectively and at scale. We engineer microbial strains, develop then improve production processes using upstream and downstream process development at our bioprocess facility and help partners tech transfer their process to scale. The three main products we work on are:
(1) Natural Products - we help partners to access and work with rare and hard-to-source natural products and producing strains, to produce novel analogues of microbial natural products and to scale-up their production.
(2) Recombinant Peptides – working in E. coli or Pichia we can develop scalable manufacturing processes designed to compete economically with synthetic processes, especially at scale.
(3) Biocatalytic Enzymes - we support the discovery and production of microbial enzymes for manufacture in our proprietary E. coli or Pichia systems and help to produce them at laboratory and pilot scale, to generate robust processes for their production and to tech transfer these processes to CDMOs enabling phase-appropriate larger scale manufacture.
Isomerase operates B2B with companies wanting to benefit from our microbial expertise to generate value in their products and progress their processes toward commercialisation. Isomerase has worked with companies throughout Europe and North America, ranging in size from two-person virtual operations to multinational companies serving a range of industries including pharmaceutical, diagnostic, agritech, consumer goods and functional materials.
(1) Natural Products - we help partners to access and work with rare and hard-to-source natural products and producing strains, to produce novel analogues of microbial natural products and to scale-up their production.
(2) Recombinant Peptides – working in E. coli or Pichia we can develop scalable manufacturing processes designed to compete economically with synthetic processes, especially at scale.
(3) Biocatalytic Enzymes - we support the discovery and production of microbial enzymes for manufacture in our proprietary E. coli or Pichia systems and help to produce them at laboratory and pilot scale, to generate robust processes for their production and to tech transfer these processes to CDMOs enabling phase-appropriate larger scale manufacture.
Isomerase operates B2B with companies wanting to benefit from our microbial expertise to generate value in their products and progress their processes toward commercialisation. Isomerase has worked with companies throughout Europe and North America, ranging in size from two-person virtual operations to multinational companies serving a range of industries including pharmaceutical, diagnostic, agritech, consumer goods and functional materials.